CN111840357A - 一种以水苏糖为主的复合微生态调节剂 - Google Patents
一种以水苏糖为主的复合微生态调节剂 Download PDFInfo
- Publication number
- CN111840357A CN111840357A CN202010750041.8A CN202010750041A CN111840357A CN 111840357 A CN111840357 A CN 111840357A CN 202010750041 A CN202010750041 A CN 202010750041A CN 111840357 A CN111840357 A CN 111840357A
- Authority
- CN
- China
- Prior art keywords
- stachyose
- bifidobacterium
- oligosaccharide
- lactobacillus
- regulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 title claims abstract description 46
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 title claims abstract description 46
- 239000002131 composite material Substances 0.000 title claims abstract description 25
- 239000006041 probiotic Substances 0.000 claims abstract description 41
- 235000018291 probiotics Nutrition 0.000 claims abstract description 41
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 239000000463 material Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 230000000529 probiotic effect Effects 0.000 claims abstract description 19
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 14
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 14
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 14
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 13
- 239000011162 core material Substances 0.000 claims abstract description 11
- 229920000742 Cotton Polymers 0.000 claims abstract description 10
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 10
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 10
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 9
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 8
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 5
- 244000005700 microbiome Species 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 8
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 8
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 8
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 8
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 8
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 8
- 235000021014 blueberries Nutrition 0.000 claims description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 7
- 229940055416 blueberry extract Drugs 0.000 claims description 7
- 235000019216 blueberry extract Nutrition 0.000 claims description 7
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001069 Raman spectroscopy Methods 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000005360 mashing Methods 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 4
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 4
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002075 main ingredient Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 239000003833 bile salt Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004211 gastric acid Anatomy 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 description 16
- 230000009286 beneficial effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000008944 intestinal immunity Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002068 microbial inoculum Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种以水苏糖为主的复合微生态调节剂,涉及固体饮料、保健食品及药品技术领域;为了解决直接添加双歧杆菌粉、嗜酸乳杆菌粉,其抗逆性和环境耐受性不高问题;具体以下组分原料:水苏糖、棉子低聚糖、低聚果糖、益生菌和辅料,水苏糖、棉子低聚糖、低聚果糖的重量份配比为2:1:1;所述益生菌为嗜酸乳杆菌、发酵乳杆菌、短双歧杆菌、干酪乳杆菌。本发明选取微生物为芯材,被包裹的益生菌仅能在动物肠道中释放,能够抵御宿主机体内高胃酸和胆盐等不利环境,与未包裹的复合益生菌相比,采用微胶囊制备技术,微生物复合菌剂的抗逆性、环境耐受性大幅度提高,更加便于其在肠道环境下功能的发挥,更便于运输和长期保存。
Description
技术领域
本发明涉及固体饮料、保健食品及药品技术领域,尤其涉及一种以水苏糖为主的复合微生态调节剂。
背景技术
肠道菌群被认为是人身体的一个重要内分泌器官,人体的健康情况与肠道菌群密切相关,益生元成分对肠道菌群和宿主的影响概括起来有以下方面:(1)调节菌群结构,增殖有益菌群,而有益菌的生长,同时也能抑制病原菌和腹泻的发生;(2)增殖的有益菌能刺激肠道免疫细胞活性,从而增强机体免疫抗病力,降低癌症发生风险;(3)有益菌分泌的酶能分解益生元产生营养物质、可以增加宿主对营养的吸收;(4)降低肠道内pH,促进矿物质吸收功能;(5)缓解乳糖不耐受症,增加排便防治便秘;(6)调节血脂和胆固醇代谢,降低血压;(7)降低龋齿发生概率,不会引起血糖升高。然而,现有技术中的益生元产品功能单一且种类单调,可供人们选择的功能食品较少。
经检索,中国专利申请号为CN02145700.X的专利,公开了一种肠道微生态调节剂,属微生态制剂范畴。主要由双歧杆菌粉、嗜酸乳杆菌粉和水苏糖组成,组份及重量份比例如下:水苏糖(含棉子糖)10%-90%,菌粉5%-75%,添加剂0-30%。上述专利中的肠道微生态调节剂存在以下不足:直接添加双歧杆菌粉、嗜酸乳杆菌粉至调节剂内,其抗逆性和环境耐受性不高。
发明内容
本发明的目的是为了解决现有技术中存在的缺点,而提出的一种以水苏糖为主的复合微生态调节剂。
为了实现上述目的,本发明采用了如下技术方案:
一种以水苏糖为主的复合微生态调节剂,包括以下组分原料:水苏糖、棉子低聚糖、低聚果糖、益生菌和辅料,水苏糖、棉子低聚糖、低聚果糖的重量份配比为2:1:1。
优选地:所述益生菌为嗜酸乳杆菌、发酵乳杆菌、短双歧杆菌、干酪乳杆菌、罗伊氏乳杆菌、拉曼乳杆菌、长双歧杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌、乳双歧杆菌、青春双歧杆菌、嗜热双歧杆菌、枯草芽孢杆菌和布拉氏酵母菌、鼠李糖双歧杆菌中的一种或多种的混合。
优选地:所述益生菌的活菌数配比为发酵乳杆菌和短双歧杆菌的菌数为109/g,乳双歧杆菌和鼠李糖双歧杆菌的菌数为108/g,罗伊氏乳杆菌和婴儿双歧杆菌的菌数为105/g。
优选地:所述益生菌为微囊化微生态的益生菌粉,芯材为微生物,益生菌微胶囊化的制备方法,包括如下工艺:
S11:将益生菌一种或多种作为芯材与壁材混合均匀,得到混合物;
S12:将混合物经低温喷雾干燥,与其余组分混合即得微囊化微生态的益生菌粉。
优选地:所述壁材为25%-55%的海藻酸丙二醇酯溶液。
优选地:所述芯材和壁材的体积比为0.06:1。
优选地:所述辅料为矫味剂、粘合剂、润滑剂、填充剂和崩解剂中的一种,辅料为蓝莓提取物。
优选地:所述以水苏糖为主的复合微生态调节剂的制备方法包括如下步骤:
S1:按各原料配比,将蓝莓捣碎成糊状,将糊状蓝莓原料倒入搅拌机内,并加入水苏糖、棉子低聚糖、低聚果糖和中药提取液,搅拌5min;
S2:将搅拌完成的原料倒入干燥箱内进行干燥处理,且干燥温度为60-90℃,干燥时间为2-4h;
S3:将干燥完成的原料倒入粉碎机内粉碎处理,过100目筛;
S4:将经S3步骤处理后的原料和微囊化微生态的益生菌粉混合均匀,得到产品;
S5:将产品倒入装袋机内装袋处理,控制每袋重量为5g,每盒装15-20袋,检验合格后包装入库。
优选地:所述产品为速溶性冻干粉剂。
本发明的有益效果为:
1.选取微生物为芯材,被包裹的益生菌仅能在动物肠道中释放,能够抵御宿主机体内高胃酸和胆盐等不利环境,与未包裹的复合益生菌相比,采用微胶囊制备技术,微生物复合菌剂的抗逆性、环境耐受性大幅度提高,更加便于其在肠道环境下功能的发挥,更便于运输和长期保存。
2.将水苏糖、蓝莓提取物、益生菌和鸡内金水解肽进行结合来作为保健食品原料调整肠道微生态,可以辅助抑制幽门螺杆菌的繁殖,修复因酒精损伤的胃粘膜,修复效果好,无副作用,可以长期食用。
3.添加水苏糖及可溶性膳食纤维或鸡内金多肽及微量元素锌,通过其协同作用,不仅能够有效改善肠道菌群结构,改善肠道免疫力,而且在促进慢性结肠炎、肠易激综合症方面具有显著的效果。
4.水苏糖能显著增殖肠道中双歧杆菌属为代表的有益菌,抑制有害菌的生长,有益菌分泌的蛋白酶、淀粉酶和脂肪酶等,促进蛋白质消化吸收,还能促进B族维生素的合成,优化宿主的免疫力。
附图说明
图1为本发明提出的一种以水苏糖为主的复合微生态调节剂的实施例1流程示意图;
图2为本发明提出的一种以水苏糖为主的复合微生态调节剂的实施例2流程示意图。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
下面详细描述本专利的实施例,所述实施例的示例在附图中示出,其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的,仅用于解释本专利,而不能理解为对本专利的限制。
在本专利的描述中,需要理解的是,术语“中心”、“上”、“下”、“前”、“后”、“左”、“右”、“竖直”、“水平”、“顶”、“底”、“内”、“外”等指示的方位或位置关系为基于附图所示的方位或位置关系,仅是为了便于描述本专利和简化描述,而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作,因此不能理解为对本专利的限制。
在本专利的描述中,需要说明的是,除非另有明确的规定和限定,术语“安装”、“相连”、“连接”、“设置”应做广义理解,例如,可以是固定相连、设置,也可以是可拆卸连接、设置,或一体地连接、设置。对于本领域的普通技术人员而言,可以根据具体情况理解上述术语在本专利中的具体含义。
实施例1:
一种以水苏糖为主的复合微生态调节剂,如图1所示,包括以下组分原料:水苏糖、棉子低聚糖、低聚果糖、益生菌和辅料,水苏糖、棉子低聚糖、低聚果糖的重量份配比为2:1:1。
所述益生菌为嗜酸乳杆菌、发酵乳杆菌、短双歧杆菌、干酪乳杆菌、罗伊氏乳杆菌、拉曼乳杆菌、长双歧杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌、乳双歧杆菌、青春双歧杆菌、嗜热双歧杆菌、枯草芽孢杆菌和布拉氏酵母菌、鼠李糖双歧杆菌中的一种或多种的混合。
所述益生菌的活菌数配比为发酵乳杆菌和短双歧杆菌的菌数为109/g,乳双歧杆菌和鼠李糖双歧杆菌的菌数为108/g,罗伊氏乳杆菌和婴儿双歧杆菌的菌数为105/g。
所述益生菌为微囊化微生态的益生菌粉,芯材为微生物,益生菌微胶囊化的制备方法,包括如下工艺:
S11:将益生菌一种或多种作为芯材与壁材混合均匀,得到混合物;
S12:将混合物经低温喷雾干燥,与其余组分混合即得微囊化微生态的益生菌粉。
进一步的,所述壁材为25%-55%的海藻酸丙二醇酯溶液。
进一步的,所述芯材和壁材的体积比为0.06:1。
所述辅料为矫味剂、粘合剂、润滑剂、填充剂和崩解剂中的一种,优选的,本实施例中辅料为蓝莓提取物。
一种以水苏糖为主的复合微生态调节剂的制备方法,包括如下步骤:
S1:按各原料配比,将蓝莓捣碎成糊状,将糊状蓝莓原料倒入搅拌机内,并加入水苏糖、棉子低聚糖、低聚果糖和中药提取液,搅拌5min;
S2:将搅拌完成的原料倒入干燥箱内进行干燥处理,且干燥温度为60-90℃,干燥时间为2-4h;
S3:将干燥完成的原料倒入粉碎机内粉碎处理,过100目筛;
S4:将经S3步骤处理后的原料和微囊化微生态的益生菌粉混合均匀,得到产品;
S5:将产品倒入装袋机内装袋处理,控制每袋重量为5g,每盒装15-20袋,检验合格后包装入库。
进一步的,所述产品为速溶性冻干粉剂。
本实施例在使用时,将水苏糖、蓝莓提取物和益生菌进行结合来作为保健食品原料调整肠道微生态,可以辅助抑制幽门螺杆菌的繁殖,修复因酒精损伤的胃粘膜,修复效果好,无副作用,可以长期食用,选取微生物为芯材,被包裹的益生菌仅能在动物肠道中释放,能够抵御宿主机体内高胃酸和胆盐等不利环境,与未包裹的复合益生菌相比,采用微胶囊制备技术,微生物复合菌剂的抗逆性、环境耐受性大幅度提高,更加便于其在肠道环境下功能的发挥,更便于运输和长期保存。
实施例2:
一种以水苏糖为主的复合微生态调节剂,如图2所示,包括以下组分原料:水苏糖、棉子低聚糖、低聚果糖、益生菌和辅料,水苏糖、棉子低聚糖、低聚果糖的重量份配比为2:1:1。
所述原料还包括鸡内金水解肽、锌和橙皮甙一种或两种以上,其中鸡内金水解肽20-85mg,锌20ug。
所述益生菌为嗜酸乳杆菌、发酵乳杆菌、短双歧杆菌、干酪乳杆菌、罗伊氏乳杆菌、拉曼乳杆菌、长双歧杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌、乳双歧杆菌、青春双歧杆菌、嗜热双歧杆菌、枯草芽孢杆菌和布拉氏酵母菌、鼠李糖双歧杆菌中的一种或多种的混合。
所述益生菌的活菌数配比为发酵乳杆菌和短双歧杆菌的菌数为109/g,乳双歧杆菌和鼠李糖双歧杆菌的菌数为108/g,罗伊氏乳杆菌和婴儿双歧杆菌的菌数为105/g。
所述益生菌为微囊化微生态的益生菌粉,芯材为微生物,益生菌微胶囊化的制备方法,包括如下工艺:
S11:将益生菌一种或多种作为芯材与壁材混合均匀,得到混合物;
S12:将混合物经低温喷雾干燥,与其余组分混合即得微囊化微生态的益生菌粉。
进一步的,所述壁材为25%-55%的海藻酸丙二醇酯溶液。
进一步的,所述芯材和壁材的体积比为0.06:1。
所述辅料为矫味剂、粘合剂、润滑剂、填充剂和崩解剂中的一种,优选的,本实施例中辅料为蓝莓提取物。
一种以水苏糖为主的复合微生态调节剂的制备方法,包括如下步骤:
S1:按各原料配比,将蓝莓捣碎成糊状,将糊状蓝莓原料倒入搅拌机内,并加入水苏糖、棉子低聚糖、低聚果糖、中药提取液、鸡内金水解肽和锌,搅拌5min;
S2:将搅拌完成的原料倒入干燥箱内进行干燥处理,且干燥温度为60-90℃,干燥时间为2-4h;
S3:将干燥完成的原料倒入粉碎机内粉碎处理,过100目筛;
S4:将经S3步骤处理后的原料和微囊化微生态的益生菌粉混合均匀,得到产品;
S5:将产品倒入装袋机内装袋处理,控制每袋重量为5g,每盒装15-20袋,检验合格后包装入库。
进一步的,所述产品的剂型为速溶性冻干粉剂。
本实施例在使用时,将水苏糖、蓝莓提取物、益生菌和鸡内金水解肽进行结合来作为保健食品原料调整肠道微生态,添加水苏糖及其恰当的用量,及可溶性膳食纤维或鸡内金多肽及微量元素锌(甘草锌、葡糖糖酸锌),通过其协同作用,不仅能够有效改善肠道菌群结构,改善肠道免疫力,而且在促进慢性结肠炎、肠易激综合症方面具有显著的效果;调节剂中的功能性水苏糖能显著增殖肠道中双歧杆菌属为代表的有益菌,抑制有害菌的生长,有益菌分泌的蛋白酶、淀粉酶和脂肪酶等,促进蛋白质消化吸收,还能促进B族维生素的合成,优化宿主的免疫力,此外,益生菌代谢产生的短链脂肪酸能降低肠道pH值进一步抑制有害菌,从而改善肠菌结构,有益菌增殖后产气增加,增加肠压,促进肠蠕动,促进排便。
实施例3:
随机选取100名患有便秘、肠易激综合征、湿疹的患者,症状表现为下腹部疼痛,腹胀,食欲不振、排便不规律等症状;腹痛多数无规律,疼痛性质多为弥慢性下腹隐痛、胀痛等,其中女性56名,年龄23-46岁之间,男性44名,年龄31-54岁之间,所有患者均已进行肠镜检查确诊,肠镜诊断标准:主要表现为点片状或条带状的红斑,病变区域往往红白相间,但以红相为主,肠粘膜粗糙不平,表现出充血,水肿,出血等现象。
在经得患者同意后食用本发明的实施例1的调节剂30日,每日食用量为5g,早晚各2.5g,食用方式根据患者喜好选取,食用本发明的调节剂期间禁止服用任何药物,并且要禁止饮酒和食用刺激性食物,30日后进行肠镜复诊,主要表现为点片状或条带状的红斑、充血,水肿,出血全面缓解,食用本发明的调节剂30天后,患有相应便秘、肠易激综合征、湿疹的治愈率为70%,症状缓解率为12.5%;总体上治愈率为82.5%。
实验例4
随机选取100名患有血糖异常并伴有局部湿疹的患者,症状表现为:空腹糖化血红糖蛋白>5.9,且身体伴有1-2处湿疹样皮损,其中女性26名,年龄23-56岁之间,男性24名,年龄31-59岁之间,所有患者均已进行糖耐量测试,证实糖耐量受损。
在经得患者同意后食用本发明的实施例2的调节剂60日,每日食用量为5g,早晚各2.5g,食用方式根据患者喜好选取,食用本发明的调节剂期间禁止服用任何药物,并且要禁止饮酒和食用刺激性食物,30日后进行糖耐量测试及糖化血红蛋白测试,食用本发明的调节剂60天后,糖耐量及湿疹同时治愈的治愈率为62.35%,仅湿疹症状缓解率为72.5%。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (9)
1.一种以水苏糖为主的复合微生态调节剂,其特征在于,包括以下组分原料:水苏糖、棉子低聚糖、低聚果糖、益生菌和辅料,水苏糖、棉子低聚糖、低聚果糖的重量份配比为2:1:1。
2.根据权利要求1所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述益生菌为嗜酸乳杆菌、发酵乳杆菌、短双歧杆菌、干酪乳杆菌、罗伊氏乳杆菌、拉曼乳杆菌、长双歧杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌、乳双歧杆菌、青春双歧杆菌、嗜热双歧杆菌、枯草芽孢杆菌和布拉氏酵母菌、鼠李糖双歧杆菌中的一种或多种的混合。
3.根据权利要求2所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述益生菌的活菌数配比为发酵乳杆菌和短双歧杆菌的菌数为109/g,乳双歧杆菌和鼠李糖双歧杆菌的菌数为108/g,罗伊氏乳杆菌和婴儿双歧杆菌的菌数为105/g。
4.根据权利要求3所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述益生菌为微囊化微生态的益生菌粉,芯材为微生物,益生菌微胶囊化的制备方法,包括如下工艺:
S11:将益生菌一种或多种作为芯材与壁材混合均匀,得到混合物;
S12:将混合物经低温喷雾干燥,与其余组分混合即得微囊化微生态的益生菌粉。
5.根据权利要求4所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述壁材为25%-55%的海藻酸丙二醇酯溶液。
6.根据权利要求5所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述芯材和壁材的体积比为0.06:1。
7.根据权利要求1-6任一所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述辅料为矫味剂、粘合剂、润滑剂、填充剂和崩解剂中的一种,辅料为蓝莓提取物。
8.根据权利要求1所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述以水苏糖为主的复合微生态调节剂的制备方法包括如下步骤:
S1:按各原料配比,将蓝莓捣碎成糊状,将糊状蓝莓原料倒入搅拌机内,并加入水苏糖、棉子低聚糖、低聚果糖和中药提取液,搅拌5min;
S2:将搅拌完成的原料倒入干燥箱内进行干燥处理,且干燥温度为60-90℃,干燥时间为2-4h;
S3:将干燥完成的原料倒入粉碎机内粉碎处理,过100目筛;
S4:将经S3步骤处理后的原料和微囊化微生态的益生菌粉混合均匀,得到产品;
S5:将产品倒入装袋机内装袋处理,控制每袋重量为5g,每盒装15-20袋,检验合格后包装入库。
9.根据权利要求8所述的一种以水苏糖为主的复合微生态调节剂,其特征在于,所述产品为速溶性冻干粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010750041.8A CN111840357A (zh) | 2020-07-30 | 2020-07-30 | 一种以水苏糖为主的复合微生态调节剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010750041.8A CN111840357A (zh) | 2020-07-30 | 2020-07-30 | 一种以水苏糖为主的复合微生态调节剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111840357A true CN111840357A (zh) | 2020-10-30 |
Family
ID=72945062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010750041.8A Pending CN111840357A (zh) | 2020-07-30 | 2020-07-30 | 一种以水苏糖为主的复合微生态调节剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111840357A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112544798A (zh) * | 2020-12-04 | 2021-03-26 | 中国海洋大学 | 一种改善大菱鲆肠道健康和机体免疫力的合生元及饲料 |
CN112813011A (zh) * | 2021-03-23 | 2021-05-18 | 北京宝源广通科技发展有限公司 | 一种干酪乳杆菌及其在制备水苏糖合生元酸奶中的应用 |
CN113841817A (zh) * | 2021-09-07 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种可以防止细胞衰老、促进细胞代谢的有益食品 |
CN115039886A (zh) * | 2022-06-09 | 2022-09-13 | 武汉隆丰园生物科技有限公司 | 一种双歧杆菌微胶囊的制备方法及应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493305A (zh) * | 2002-10-29 | 2004-05-05 | 西安大鹏生物科技股份有限公司 | 一种肠道微生态调节剂 |
CN101496822A (zh) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | 复合益生菌微生态制剂及制备方法 |
CN104839684A (zh) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 幽门螺杆菌相关性胃炎医学配方食品 |
CN104839683A (zh) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 便秘医学配方食品 |
CN105707772A (zh) * | 2016-04-01 | 2016-06-29 | 邵素英 | 一种可改善肠道性能的蓝莓复合粉及其制备方法 |
CN105831645A (zh) * | 2016-04-01 | 2016-08-10 | 北京科慧通智慧科技有限公司 | 一种益生性蓝莓复合粉及其制备方法 |
CN107212415A (zh) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | 一种五联益生菌营养粉及其制备方法 |
CN107495049A (zh) * | 2017-10-17 | 2017-12-22 | 广东达明益派生物科技有限公司 | 用于制备具有润肠通便功能的益生菌发酵果蔬饮料的组合物、含组合物的饮料及其制备方法 |
CN107950707A (zh) * | 2016-10-17 | 2018-04-24 | 福建奥正投资发展有限公司 | 自调配饮料组合物,及其制备方法和应用 |
CN109275905A (zh) * | 2017-07-21 | 2019-01-29 | 广州医宗植物化妆品有限公司 | 一种多种植物复配营养补充剂的制备方法 |
CN110522061A (zh) * | 2019-08-28 | 2019-12-03 | 青岛职业技术学院 | 一种微胶囊及其制备方法 |
CN111150068A (zh) * | 2018-11-06 | 2020-05-15 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种以复合材料为壁材的益生菌微胶囊及其制备方法 |
-
2020
- 2020-07-30 CN CN202010750041.8A patent/CN111840357A/zh active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493305A (zh) * | 2002-10-29 | 2004-05-05 | 西安大鹏生物科技股份有限公司 | 一种肠道微生态调节剂 |
CN101496822A (zh) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | 复合益生菌微生态制剂及制备方法 |
CN104839684A (zh) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 幽门螺杆菌相关性胃炎医学配方食品 |
CN104839683A (zh) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 便秘医学配方食品 |
CN105707772A (zh) * | 2016-04-01 | 2016-06-29 | 邵素英 | 一种可改善肠道性能的蓝莓复合粉及其制备方法 |
CN105831645A (zh) * | 2016-04-01 | 2016-08-10 | 北京科慧通智慧科技有限公司 | 一种益生性蓝莓复合粉及其制备方法 |
CN107950707A (zh) * | 2016-10-17 | 2018-04-24 | 福建奥正投资发展有限公司 | 自调配饮料组合物,及其制备方法和应用 |
CN107212415A (zh) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | 一种五联益生菌营养粉及其制备方法 |
CN109275905A (zh) * | 2017-07-21 | 2019-01-29 | 广州医宗植物化妆品有限公司 | 一种多种植物复配营养补充剂的制备方法 |
CN107495049A (zh) * | 2017-10-17 | 2017-12-22 | 广东达明益派生物科技有限公司 | 用于制备具有润肠通便功能的益生菌发酵果蔬饮料的组合物、含组合物的饮料及其制备方法 |
CN111150068A (zh) * | 2018-11-06 | 2020-05-15 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种以复合材料为壁材的益生菌微胶囊及其制备方法 |
CN110522061A (zh) * | 2019-08-28 | 2019-12-03 | 青岛职业技术学院 | 一种微胶囊及其制备方法 |
Non-Patent Citations (5)
Title |
---|
于守洋,等主编: "《中国保健食品的进展》", 31 January 2001, 人民卫生出版社 * |
吴克刚,等主编: "《食品微胶囊技术》", 31 July 2006, 中国轻工业出版社 * |
常树山,等: "活性益生菌乳饮料复合稳定剂配方优化", 《农业工程》 * |
熊德鑫,编著: "《现代微生态学》", 31 March 2000, 中国科学技术出版社 * |
迟玉杰,主编: "《保健食品学》", 31 May 2016, 中国轻工业出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112544798A (zh) * | 2020-12-04 | 2021-03-26 | 中国海洋大学 | 一种改善大菱鲆肠道健康和机体免疫力的合生元及饲料 |
CN112544798B (zh) * | 2020-12-04 | 2022-05-13 | 中国海洋大学 | 一种改善大菱鲆肠道健康和机体免疫力的合生元及饲料 |
CN112813011A (zh) * | 2021-03-23 | 2021-05-18 | 北京宝源广通科技发展有限公司 | 一种干酪乳杆菌及其在制备水苏糖合生元酸奶中的应用 |
CN113841817A (zh) * | 2021-09-07 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种可以防止细胞衰老、促进细胞代谢的有益食品 |
CN115039886A (zh) * | 2022-06-09 | 2022-09-13 | 武汉隆丰园生物科技有限公司 | 一种双歧杆菌微胶囊的制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111840357A (zh) | 一种以水苏糖为主的复合微生态调节剂 | |
CA2199140C (en) | Probiotic compositions | |
US8066986B2 (en) | Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms | |
JP2004524836A (ja) | プロバイオティックスの組合せ | |
EP2269465A1 (en) | Compositions comprising Bifidobacterium adolescentis | |
WO2007043563A1 (ja) | 腸内フローラ改善用組成物 | |
CN111387395A (zh) | 一种益生菌固体饮品及其制备方法 | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN110150667A (zh) | 一种提升免疫力并调节肠道功能的保健品及其制备方法 | |
CN113559131A (zh) | 一种用于改善肠胃的益生菌粉 | |
CN111227261A (zh) | 一种益生元组合物及其应用 | |
CN109022323A (zh) | 一种瑞士乳杆菌复合剂及其制备方法和应用 | |
CN105249480A (zh) | 一种膳食纤维和双歧杆菌的咀嚼片及其制备方法 | |
CN115671132B (zh) | 一种益生菌和益生元的组合物及其应用 | |
CN112273657A (zh) | 用于预防或改善过敏性疾病的益生菌组合物、制法和应用 | |
JP6945888B1 (ja) | 免疫機能向上用組成物 | |
JP4135505B2 (ja) | 腸内有用菌定着増殖促進食品 | |
CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
JP3382871B2 (ja) | 健康食品 | |
JP3409038B2 (ja) | キャベツ発酵エキスの製造方法 | |
JP2004250337A (ja) | アレルギー疾患改善用製剤 | |
AU687253C (en) | Probiotic compositions | |
KR102366898B1 (ko) | 천연 추출물과 프로바이오틱스를 포함하여 위와 장 건강에 도움을 주는 조성물 | |
JP7257665B2 (ja) | 経口組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |